COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00101634
Recruitment Status : Completed
First Posted : January 13, 2005
Last Update Posted : June 8, 2011
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Brief Summary:
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: Paliperidone palmitate Phase 3

Detailed Description:
Many patients with schizophrenia have difficulty adhering to a daily oral treatment regimen. Long-acting injectable (LAI) formulations may provide therapeutic plasma concentrations over several weeks, thereby eliminating the need for daily oral medication and making compliance easier. This is a randomized (patients will be assigned to different treatment groups based solely on chance), double-blind (neither the patient nor the physician will know if placebo or drug is being given and at what dose), placebo-controlled, parallel group, multicenter, dose-response study in adults who have schizophrenia. The study consists of a screening period of no more than 7 days and a 13-week double-blind treatment period. The screening period includes 4 days for tolerability testing, if necessary. In the double-blind treatment period, patients will be randomly assigned to 1 of 4 treatment groups (3 fixed doses of paliperidone palmitate or placebo) to receive 4 i.m. injections of paliperidone palmitate or placebo on Days 1, 8, 36, and 64. The study, including the screening period, will last approximately 14 weeks. Efficacy will be assessed throughout the study using the Positive and Negative Symptom Scale for Schizophrenia (PANSS), the Clinical Global Impression-Severity (CGI-S), and the Personal and Social Performance Scale (PSP). Safety will be evaluated throughout the study by monitoring adverse events, extrapyramidal symptom (EPS) rating scales scores, clinical laboratory test results; vital signs and body weight measurements; electrocardiograms (ECGs); and physical examination findings. In addition, the tolerability of injections will be assessed. ER OROS paliperidone 3 mg/day for 4 days. Injections (i.m.) of paliperidone palmitate (25, 50, or 100 mg eq.) will be given on Days 1, 8, 36, and 64.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 518 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia
Study Start Date : December 2004
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Primary Outcome Measures :
  1. Change in total PANSS score from baseline to the end of the double blind treatment period.

Secondary Outcome Measures :
  1. PSP and CGI-S scores from baseline to the end of of the double-blind treatment. Incidence of adverse events, labs and ECGs throughout study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who meet diagnostic criteria for schizophrenia according to DSM-IV for at least 1 year
  • meet PANSS score criteria
  • have body mass index (BMI) of >15.0 kilogram(kg)/meter (m)2.

Exclusion Criteria:

  • Patients who have primary active DSM-IV Axis I diagnosis other than schizophrenia
  • have a decrease of >/=25% in the PANSS score
  • have DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation (nicotine and caffeine dependence are not exclusionary)
  • have history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications
  • have any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)
  • have significant risk of suicidal, homicidal or violent ideation or behavior
  • current presence of any significant or unstable medication condition
  • treatment with any protocol disallowed therapies
  • clinically significant result from screening laboratory or ECG.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00101634

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Layout table for investigator information
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Additional Information:
Layout table for additonal information Identifier: NCT00101634    
Other Study ID Numbers: CR003562
First Posted: January 13, 2005    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: January 2011
Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Paliperidone palmitate
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Paliperidone Palmitate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents